Celine Halioua

Four years ago I founded Loyal with a simple vision — to bring to market the first drug explicitly approved and labeled for healthy lifespan extension. Loyal was only a few months old and about five people when we decided to begin by targeting the abnormally short lifespan of large breed dogs with a drug program we code-named LOY-001. 

 what we believe to be the FDA’s first-ever formal acceptance that a drug can be developed and approved to extend lifespan. 

In regulatory parlance, we have completed the technical effectiveness portion of our conditional approval application for LOY-001’s use in large dog lifespan extension. 

As there was no established regulatory path for a lifespan extension drug, we had to design from scratch a scientifically strong and logistically feasible way to demonstrate efficacy of an aging drug. This process took more than four years, resulting in the 2,300+ page technical section now approved by the FDA. It included interventional studies of LOY-001 in an FDA-accepted model of canine aging and an observational (no-drug) study of 451 dogs.

Our interventional studies with LOY-001 showed that the drug improved clinically-relevant aging parameters. We assessed these in laboratory studies using a dog model that represents accelerated aging. We then correlated those results with quality of life scores in the observational study, as independently measured by dog owners, and health outcomes as measured by veterinarians. This was key to show that the biological benefits of the drug are linked to clinically relevant outcomes.

From our data, the FDA believes LOY-001 is likely to be effective for large dog lifespan extension in the real world. Once we satisfactorily complete safety and manufacturing sections and other requirements, vets will be able to prescribe LOY-001 to extend the lifespan of large dogs while we complete the confirmatory pivotal lifespan extension study in parallel.

If you have a large- or giant-breed dog you may be familiar with the sad reality that these large dogs tend to live shorter lives than smaller dogs — often by half.

Giant breeds like Great Danes have an average lifespan of 7-10 years, while tiny breeds like the Chihuahua live 14-16 years. (source: AKC, O’Neill et al 2013). Not only do they have varying lifespans, but it’s possible that aging and age-associated disease progresses differently among different breeds.

This is unusual — very few if any other animals have such an extreme lifespan variation 

 the same species. Generally, the larger a mammal is, the longer its expected lifespan — a mouse may live two to three years, while elephants can live over 60 years. 

Part of this lifespan disparity comes from the process of selective breeding that “created” these dog breeds.  Historical selective breeding is understood to have created genetic issues like hip dysplasia in German Shepherds and breathing issues in brachycephalic dogs. In large- and giant-breed dogs, breeding for size caused these dogs to have highly elevated levels of IGF-1, a hormone that drives cell growth. High IGF-1 effectively drives these dogs to grow large when they’re young, but high IGF-1 levels in adult dogs are believed to accelerate their aging and reduce their healthy lifespan.

LOY-001 extends lifespan in part by reducing IGF-1 to levels seen in smaller-breed dogs. The IGF-1 axis is one of the most well-studied longevity pathways. In model organisms from 

to mice, reducing IGF-1 extends healthy lifespan, and increasing IGF-1 shortens healthy lifespan. In humans, certain centenarians have been shown to have genetically lower levels of IGF-1.

The breakthrough moment for Loyal was connecting the biological mechanism of big dogs’ size to their short lifespan, and recognizing the big-dog-short-lifespan phenotype may not be inherent, but instead a type of “accelerated aging disorder”.

We designed LOY–001 as a long-acting injectable administered by your veterinarian every three to six months. In parallel, through our 

 partnership with Crinetics, we’re also developing LOY-003, a daily pill to address this same IGF-1 over-expression. 

A regulatory process that ensures safety and effectiveness

Our product strategy has always been centered on earning FDA approval. While more challenging, time intensive, and expensive, I believe achieving FDA approval is critical to demonstrating the scientific legitimacy of lifespan extension drugs.

Most people know that the FDA has a rigorous system for ensuring that pharmaceutical products are safe and effective for humans. The same is true for veterinary medications — the drugs your vet prescribes to your dog, like the Rimadyl my senior Rottweiler takes for her arthritis, have been tested extensively and are regularly monitored by the FDA Center for Veterinary Medicine.

To obtain approval to sell the drug, companies must present extensive data to the FDA in three core areas:

The health and safety of dogs is our top priority in all things, and there’s no higher bar in the United States than the FDA. 

Conditional approval helps us help dogs sooner

The FDA’s expanded conditional approval process allows companies to bring certain products to patients while conducting longer effectiveness studies, specifically when the product meets an important unmet need. This helps us get treatment as early as possible to older dogs who need it most.

To receive conditional approval, the product must meet the same rigorous safety and manufacturing standards as drugs that are fully approved. To stay on the market beyond the five-year conditional approval period, we must demonstrate full efficacy — in our case lifespan extension — in a pivotal study. 

Each milestone we’ve achieved in this methodical, evidence-based process has demonstrated steady progress toward our vision of helping dogs live longer and stay healthy as they age.

This one is especially important because it marks a key step toward FDA approval based on credible, carefully reviewed data.

This process will make it possible for us to bring our products into veterinary clinics everywhere, and lead the charge on a new approach to age-related disease and decline.

That will ultimately mean more healthy years for the dogs we love — and that’s why we’re here.

Thank you so much to the Loyal team for your intelligence, creativity, and determination to reach today’s milestone. Current and former team members who directly contributed to this milestone include: Alex Naka, Ashley Tovar, Ben Parsons, Brennen McKenzie, Dina Juarez-Salinas, Divya Shiroor, Elena Silva, Ellen Ratcliff, Entonio Marietti, Erin McCandless, Frances Chen, Jess Graves, Jessica Austriaco, Jessie George, Julie Vaughn, Kaitlyn Super, Karen Greenwood, Katya Tucker, Matt Peloquin, Michael LaCroix-Fralish, Michelle Nelson, Phil Frankino, Tennery Carttar, and Tyler McQuade. 

Thank you to our earliest investors and advisors, including but not limited to Dave Petrick, Greg Rosen, Josh Kopelman, Laura Deming, Linda Rhodes, and Taylor Greene, who believed in this crazy vision long before it was rational or sensible to do so. 

Here’s what the press is saying this morning:

Could a Drug Give Your Pet More Dog Years?

A Life-Extension Drug for Big Dogs Is Getting Closer to Reality

An anti-aging drug for dogs promises to win owners more time with old pets. It could be FDA-approved soon.

The Secrets of Anti-Aging, Gleaned From Your Dog

S.F. startup that wants to help dogs live longer just got FDA backing

Life-Extending Drug For Big Dogs Moves One Step Closer To FDA Approval

Extending dog years: New drug to increase lifespan of dogs, company awaiting FDA approval

FDA Center for Veterinary Medicine agrees Loyal’s data supports reasonable expectation of effectiveness for large dog lifespan extension

Four years ago I founded Loyal with a simple vision — to bring to market the first drug explicitly approved and labeled for healthy lifespan extension. Loyal was only a few months old and about five people when we decided to begin by targeting the abnormally short lifespan of large breed dogs with a drug program we code-named LOY-001.&nbsp;



Today, I’m so proud to announce that <a href="https://www.businesswire.com/news/home/20231127326868/en/FDA-Agrees-Loyal-Data-Supports-Reasonable-Expectation-of-Effectiveness-for-Large-Dog-Lifespan-Extension">Loyal has earned</a> what we believe to be the FDA’s first-ever formal acceptance that a drug can be developed and approved to extend lifespan. In regulatory parlance, we have completed the technical effectiveness portion of our conditional approval application for LOY-001’s use in large dog lifespan extension.&nbsp;



As there was no established regulatory path for a lifespan extension drug, we had to design from scratch a scientifically strong and logistically feasible way to demonstrate efficacy of an aging drug. This process took more than four years, resulting in the 2,300+ page technical section now approved by the FDA. It included interventional studies of LOY-001 in an FDA-accepted model of canine aging and an observational (no-drug) study of 451 dogs.



Our interventional studies with LOY-001 showed that the drug improved clinically-relevant aging parameters. We assessed these in laboratory studies using a dog model that represents accelerated aging. We then correlated those results with quality of life scores in the observational study, as independently measured by dog owners, and health outcomes as measured by veterinarians. This was key to show that the biological benefits of the drug are linked to clinically relevant outcomes.



From our data, the FDA believes LOY-001 is likely to be effective for large dog lifespan extension in the real world. Once we satisfactorily complete safety and manufacturing sections and other requirements, vets will be able to prescribe LOY-001 to extend the lifespan of large dogs while we complete the confirmatory pivotal lifespan extension study in parallel.







<h2 class="wp-block-heading">What this means for large-breed dogs</h2>



If you have a large- or giant-breed dog you may be familiar with the sad reality that these large dogs tend to live shorter lives than smaller dogs — often by half.



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dog-small-dog-great-dane-chihuahua-average-lifespan-aging-1-1024x576.jpg" alt="Giant breeds like Great Danes have an average lifespan of 7-10 years, while tiny breeds like the Chihuahua live 14-16 years. (source: AKC, O’Neill et al 2013). Not only do they have varying lifespans, but it’s possible that aging and age-associated disease progresses differently among different breeds.
" class="wp-image-924" srcset="https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dog-small-dog-great-dane-chihuahua-average-lifespan-aging-1-1024x576.jpg 1024w, https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dog-small-dog-great-dane-chihuahua-average-lifespan-aging-1-300x169.jpg 300w, https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dog-small-dog-great-dane-chihuahua-average-lifespan-aging-1-768x432.jpg 768w, https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dog-small-dog-great-dane-chihuahua-average-lifespan-aging-1-1536x864.jpg 1536w, https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dog-small-dog-great-dane-chihuahua-average-lifespan-aging-1.jpg 1999w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Giant breeds like Great Danes have an average lifespan of 7-10 years, while tiny breeds like the Chihuahua live 14-16 years. (source: AKC, O’Neill et al 2013). Not only do they have varying lifespans, but it’s possible that aging and age-associated disease progresses differently among different breeds.</figcaption></figure>



This is unusual — very few if any other animals have such an extreme lifespan variation within the same species. Generally, the larger a mammal is, the longer its expected lifespan — a mouse may live two to three years, while elephants can live over 60 years.&nbsp;



Part of this lifespan disparity comes from the process of selective breeding that “created” these dog breeds.&nbsp; Historical selective breeding is understood to have created genetic issues like hip dysplasia in German Shepherds and breathing issues in brachycephalic dogs. In large- and giant-breed dogs, breeding for size caused these dogs to have highly elevated levels of IGF-1, a hormone that drives cell growth. High IGF-1 effectively drives these dogs to grow large when they’re young, but high IGF-1 levels in adult dogs are believed to accelerate their aging and reduce their healthy lifespan.



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dogs-IGF-1-eigenmann-et-al-1984-Maxwell-et-al-1998-1024x576.jpg" alt="" class="wp-image-927" srcset="https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dogs-IGF-1-eigenmann-et-al-1984-Maxwell-et-al-1998-1024x576.jpg 1024w, https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dogs-IGF-1-eigenmann-et-al-1984-Maxwell-et-al-1998-300x169.jpg 300w, https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dogs-IGF-1-eigenmann-et-al-1984-Maxwell-et-al-1998-768x432.jpg 768w, https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dogs-IGF-1-eigenmann-et-al-1984-Maxwell-et-al-1998-1536x864.jpg 1536w, https://blog-admin.loyalfordogs.com/wp-content/uploads/2023/11/large-dogs-IGF-1-eigenmann-et-al-1984-Maxwell-et-al-1998.jpg 1999w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



LOY-001 extends lifespan in part by reducing IGF-1 to levels seen in smaller-breed dogs. The IGF-1 axis is one of the most well-studied longevity pathways. In model organisms from C. elegans to mice, reducing IGF-1 extends healthy lifespan, and increasing IGF-1 shortens healthy lifespan. In humans, certain centenarians have been shown to have genetically lower levels of IGF-1.



The breakthrough moment for Loyal was connecting the biological mechanism of big dogs’ size to their short lifespan, and recognizing the big-dog-short-lifespan phenotype may not be inherent, but instead a type of “accelerated aging disorder”.



We designed LOY–001 as a long-acting injectable administered by your veterinarian every three to six months. In parallel, through our <a href="https://loyalfordogs.com/posts/announcing-our-partnership-with-crinetics-pharmaceuticals">recently-announced</a> partnership with Crinetics, we’re also developing LOY-003, a daily pill to address this same IGF-1 over-expression.&nbsp;







<h2 class="wp-block-heading">A regulatory process that ensures safety and effectiveness</h2>



Our product strategy has always been centered on earning FDA approval. While more challenging, time intensive, and expensive, I believe achieving FDA approval is critical to demonstrating the scientific legitimacy of lifespan extension drugs.



Most people know that the FDA has a rigorous system for ensuring that pharmaceutical products are safe and effective for humans. The same is true for veterinary medications — the drugs your vet prescribes to your dog, like the Rimadyl my senior Rottweiler takes for her arthritis, have been tested extensively and are regularly monitored by the FDA Center for Veterinary Medicine.



To obtain approval to sell the drug, companies must present extensive data to the FDA in three core areas:



<ol class="wp-block-list">
<li>Efficacy — It does what it says it will do; in our case, it extends the lifespan of dogs.</li>



<li>Safety — It’s proven safe for dogs, and any side effects are well-understood and documented.</li>



<li>Manufacturing — We can manufacture it at a consistently high quality, at scale.</li>
</ol>



The health and safety of dogs is our top priority in all things, and there’s no higher bar in the United States than the FDA.&nbsp;



<h2 class="wp-block-heading">Conditional approval helps us help dogs sooner</h2>



The FDA’s expanded conditional approval process allows companies to bring certain products to patients while conducting longer effectiveness studies, specifically when the product meets an important unmet need. This helps us get treatment as early as possible to older dogs who need it most.



To receive conditional approval, the product must meet the same rigorous safety and manufacturing standards as drugs that are fully approved. To stay on the market beyond the five-year conditional approval period, we must demonstrate full efficacy — in our case lifespan extension — in a pivotal study.&nbsp;



<h2 class="wp-block-heading">What this means for all dogs</h2>



Each milestone we’ve achieved in this methodical, evidence-based process has demonstrated steady progress toward our vision of helping dogs live longer and stay healthy as they age.



This one is especially important because it marks a key step toward FDA approval based on credible, carefully reviewed data.



This process will make it possible for us to bring our products into veterinary clinics everywhere, and lead the charge on a new approach to age-related disease and decline.



That will ultimately mean more healthy years for the dogs we love — and that’s why we’re here.



——————



Thank you so much to the Loyal team for your intelligence, creativity, and determination to reach today’s milestone. Current and former team members who directly contributed to this milestone include: Alex Naka, Ashley Tovar, Ben Parsons, Brennen McKenzie, Dina Juarez-Salinas, Divya Shiroor, Elena Silva, Ellen Ratcliff, Entonio Marietti, Erin McCandless, Frances Chen, Jess Graves, Jessica Austriaco, Jessie George, Julie Vaughn, Kaitlyn Super, Karen Greenwood, Katya Tucker, Matt Peloquin, Michael LaCroix-Fralish, Michelle Nelson, Phil Frankino, Tennery Carttar, and Tyler McQuade.&nbsp;



Thank you to our earliest investors and advisors, including but not limited to Dave Petrick, Greg Rosen, Josh Kopelman, Laura Deming, Linda Rhodes, and Taylor Greene, who believed in this crazy vision long before it was rational or sensible to do so.&nbsp;



——————



Here&#8217;s what the press is saying this morning:



New York Times <span style="font-size: 11pt; font-family: Inter, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline;">— <a href="https://www.nytimes.com/2023/11/28/science/longevity-drugs-dogs.html" target="_blank" rel="noreferrer noopener">Could a Drug Give Your Pet More Dog Years?</a>



WIRED — <a href="https://www.wired.com/story/a-life-extension-drug-for-big-dogs-is-getting-closer-to-reality/" target="_blank" rel="noreferrer noopener">A Life-Extension Drug for Big Dogs Is Getting Closer to Reality</a>



Business Insider — <a href="https://www.businessinsider.com/longevity-drug-for-dogs-moves-closer-to-fda-approval-loyal-2023-11?r=US&amp;IR=T" target="_blank" rel="noreferrer noopener">An anti-aging drug for dogs promises to win owners more time with old pets. It could be FDA-approved soon.</a>



The Wall Street Journal — <a href="https://www.wsj.com/health/wellness/dog-longevity-anti-aging-loyal-a1f39cb2?reflink=integratedwebview_share">The Secrets of Anti-Aging, Gleaned From Your Dog</a>



San Francisco Chronicle — <a href="https://www.sfchronicle.com/sf/article/s-f-startup-wants-help-dogs-live-longer-got-fda-18522309.php" target="_blank" rel="noreferrer noopener">S.F. startup that wants to help dogs live longer just got FDA backing</a>



IFLScience — <a href="https://www.iflscience.com/life-extending-drug-for-big-dogs-moves-one-step-closer-to-fda-approval-71772">Life-Extending Drug For Big Dogs Moves One Step Closer To FDA Approval</a>



USA Today — <a href="https://www.usatoday.com/story/news/nation/2023/11/30/dogs-drug-lifespan-extended-fda-biotech-company-loyal/71751432007/" target="_blank" rel="noreferrer noopener">Extending dog years: New drug to increase lifespan of dogs, company awaiting FDA approval</a>

, for the excellent piece. This round brings Loyal’s total financing to over $125M.

I started Loyal four and a half years ago as a naive 24 year old with an idea that literally had people laugh in my face — FDA-approved dog lifespan extension drugs. Since then, Loyal has created the 

 for a lifespan extension drug, earned FDA acceptance of the 

 in our pivotal lifespan extension study. I am so proud of the precedent we have set and the scientific rigor we have brought to an extremely challenging and important problem. 

Our $45M Series B was led by Bain Capital Ventures, a new investor in the company who brings growth and consumer expertise. We welcomed Valor Equity Partners (Jon Shulkin) as a new investor. And Khosla Ventures (Vinod Khosla), First Round Capital (Josh Kopelman), Box Group (Greg Rosen), Quiet Capital (David Greenbaum + Daniel Gruneberg), Collaborative Fund (Craig Shapiro), and Todd & Rahul, doubled or tripled down on their previous investments in the company. The round was near 2X oversubscribed and at a significant markup to our 2021 Series A.1

This new capital fuels us to very hopefully2 bring the first FDA-approved lifespan extension drug to market. We have the data, the team, and the path forward — this capital was the last puzzle piece to ensure that, if our vision is possible, we will achieve it. 

Funding from this round will help us reach future milestones: 

Building dog longevity drugs does not have a large margin for error, and I rely on our investors to ensure we continuously level up. I appreciate so much the continued belief of incumbent investors including Greg Rosen (who convinced me to start Loyal back in 2019), Josh Kopelman (my growth rate barometer), and Vinod Khosla (whose plans are measured in centuries). I admire both the rigor and leap of faith required of new investors Kevin Zhang and Jon Shulkin — including brainstorming sessions over Adeni chai (Kevin) and cider (Jon).  

It is the honor of a lifetime to build Loyal with this team of scientists, veterinarians, creatives, operators, animal lovers, and investors. We are committed to delivering our dog longevity drugs to patients and veterinarians, and with it building a new pharmaceutical company focused on the biology of aging and healthy lifespan extension.  

1Even high interest rates can’t stop dog longevity drugs.

2While I am a trained scientist, I am also 

 superstitious and you will not catch me mentioning FDA approval without many caveats 🙂

$125M to extend dog lifespan

Today we are <a href="https://www.businesswire.com/news/home/20240321591608/en/Loyal-Announces-45-Million-Ser[…]DA-Approved-Dog-Lifespan-Extension-Drug-for-Veterinary-Use">announcing</a> Loyal’s $45M Series B. Thank you, <a href="https://www.wsj.com/articles/dog-longevity-startup-loyal-secures-45-million-in-funding-23d85cf1?st=jlgyle3tong0t4b&amp;reflink=desktopwebshare_permalink">Wall Street Journal</a>, for the excellent piece. This round brings Loyal’s total financing to over $125M.



I started Loyal four and a half years ago as a naive 24 year old with an idea that literally had people laugh in my face — FDA-approved dog lifespan extension drugs. Since then, Loyal has created the <a href="https://longevity.technology/news/first-longevity-clinical-study-design-fetches-fda-approval/">first regulatory path</a> for a lifespan extension drug, earned FDA acceptance of the <a href="https://www.nytimes.com/2023/11/28/science/longevity-drugs-dogs.html">effectiveness dossier</a> for LOY-001, been on the <a href="https://www.wired.com/story/the-search-for-a-pill-for-dog-and-human-longevity/">cover of WIRED</a>, and dosed the <a href="https://loyalfordogs.com/posts/meet-boo-first-stay-study-dog-dosed">first dog</a> in our pivotal lifespan extension study. I am so proud of the precedent we have set and the scientific rigor we have brought to an extremely challenging and important problem.&nbsp;



Our $45M Series B was led by Bain Capital Ventures, a new investor in the company who brings growth and consumer expertise. We welcomed Valor Equity Partners (Jon Shulkin) as a new investor. And Khosla Ventures (Vinod Khosla), First Round Capital (Josh Kopelman), Box Group (Greg Rosen), Quiet Capital (David Greenbaum + Daniel Gruneberg), Collaborative Fund (Craig Shapiro), and Todd &amp; Rahul, doubled or tripled down on their previous investments in the company. The round was near 2X oversubscribed and at a significant markup to our 2021 Series A.1



This new capital fuels us to very hopefully2 bring the first FDA-approved lifespan extension drug to market. We have the data, the team, and the path forward — this capital was the last puzzle piece to ensure that, if our vision is possible, we will achieve it.&nbsp;



Funding from this round will help us reach future milestones:&nbsp;



<ol class="wp-block-list">
<li>FDA manufacturing, safety, and reasonable expectation of efficacy (RXE) dossier approval for LOY-002, our product for senior dog lifespan extension</li>



<li>Market launch of our first product, and build out of our distribution and commercial functions for nationwide supply&nbsp;</li>



<li>Complete enrollment in and execution of our STAY pivotal lifespan extension study for LOY-002</li>



<li>Continued development of LOY-001 (injectable) and LOY-003 (daily pill) for large dog lifespan extension, including LOY-003 RXE submission and final commercial formulation</li>
</ol>



Building dog longevity drugs does not have a large margin for error, and I rely on our investors to ensure we continuously level up. I appreciate so much the continued belief of incumbent investors including Greg Rosen (who convinced me to start Loyal back in 2019), Josh Kopelman (my growth rate barometer), and Vinod Khosla (whose plans are measured in centuries). I admire both the rigor and leap of faith required of new investors Kevin Zhang and Jon Shulkin — including brainstorming sessions over Adeni chai (Kevin) and cider (Jon).&nbsp;&nbsp;



It is the honor of a lifetime to build Loyal with this team of scientists, veterinarians, creatives, operators, animal lovers, and investors. We are committed to delivering our dog longevity drugs to patients and veterinarians, and with it building a new pharmaceutical company focused on the biology of aging and healthy lifespan extension.&nbsp;&nbsp;



C



1Even high interest rates can&#8217;t stop dog longevity drugs. 2While I am a trained scientist, I am also deeply superstitious and you will not catch me mentioning FDA approval without many caveats 🙂

I’m excited to share that Linda Rhodes, VMD, PhD, has joined our Board of Directors. There are few people who have the breadth and depth of experience across science, veterinary medicine, and entrepreneurship that Linda does. We’re fortunate to have her as part of the Loyal team.

I have long looked up to Linda and consider her a mentor and a friend. Linda has seen it all — from living and working on a feminist dairy cow commune in California to developing three FDA-approved animal health drugs in five years and sitting on the Board of one of the world largest animal health companies. I am honored to learn from her. 

Linda’s expertise in the science and regulation of developing animal health drugs are invaluable to Loyal. We are at an exciting inflection point — aiming to launch our first product to market next year, LOY-002 for senior dogs. We also continue to develop LOY-001 and LOY-003, the large- and giant-breed therapies in our pipeline. Across our portfolio, we will benefit from tapping into Linda’s experience of bringing novel animal drug therapies to market. 

I’m encouraged by the progress we are making across all aspects of the business toward realizing our mission of helping dogs live longer, healthier lives. And I’m inspired by the trails that Linda has blazed ahead of us. 

Please join me in welcoming Linda to Loyal!

Linda Rhodes joins the Loyal Board of Directors

I’m excited to share that Linda Rhodes, VMD, PhD, has joined our Board of Directors. There are few people who have the breadth and depth of experience across science, veterinary medicine, and entrepreneurship that Linda does. We’re fortunate to have her as part of the Loyal team. I have long looked up to Linda and consider her a mentor and a friend. Linda has seen it all — from living and working on a feminist dairy cow commune in California to developing three FDA-approved animal health drugs in five years and sitting on the Board of one of the world largest animal health companies. I am honored to learn from her.&nbsp;



Linda’s expertise in the science and regulation of developing animal health drugs are invaluable to Loyal. We are at an exciting inflection point — aiming to launch our first product to market next year, LOY-002 for senior dogs. We also continue to develop LOY-001 and LOY-003, the large- and giant-breed therapies in our pipeline. Across our portfolio, we will benefit from tapping into Linda’s experience of bringing novel animal drug therapies to market.&nbsp;



I’m encouraged by the progress we are making across all aspects of the business toward realizing our mission of helping dogs live longer, healthier lives. And I’m inspired by the trails that Linda has blazed ahead of us.&nbsp;



Please join me in welcoming Linda to Loyal!